Turnstone Biologics Corp.

0.44
-0.01 (-2.22%)
At close: Feb 10, 2025, 11:20 AM
undefined%
Bid 0.44
Market Cap 10.18M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.28
PE Ratio (ttm) -0.19
Forward PE n/a
Analyst Hold
Ask 0.45
Volume 49,108
Avg. Volume (20D) 196,343
Open 0.44
Previous Close 0.45
Day's Range 0.43 - 0.47
52-Week Range 0.40 - 5.75
Beta undefined

About TSBX

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical dev...

Industry Biotechnology
Sector Healthcare
IPO Date Jul 21, 2023
Employees 80
Stock Exchange NASDAQ
Ticker Symbol TSBX

Analyst Forecast

According to 2 analyst ratings, the average rating for TSBX stock is "Hold." The 12-month stock price forecast is $2.12, which is an increase of 381.82% from the latest price.

Buy 50.00%
Hold 50.00%
Sell 0.00%
Stock Forecasts
6 days ago
+11.28%
Turnstone Biologics shares are trading higher afte... Unlock content with Pro Subscription
5 months ago
-61.93%
Turnstone Biologics shares are trading lower after the company reported worse-than-expected Q2 EPS results.